-Axios Report
Blueprint Medicines Submits Supplemental New Drug Application To FDA For AYVAKIT For Treatment Of Indolent Systemic Mastocytosis
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM).
